Clin Exp Vaccine Res.  2020 Jan;9(1):64-67. 10.7774/cevr.2020.9.1.64.

Seroprevalence of mumps in healthcare workers in South Korea

• Kim SK
• Jung J
• Kwak SH
• Hong MJ
• Kim SH

• KMID: 2470839
• DOI: http://doi.org/10.7774/cevr.2020.9.1.64

Abstract

Mumps is contagious disease and maintaining immunity to mumps in healthcare worker (HCW) is important for preventing transmission in the hospital. We evaluated the seroprevalence of mumps in HCWs in a tertiary care hospital in Republic of Korea. A total of 6,055 HCWs born between 1950 and 1995 underwent antibody testing. The overall seropositivity rate of mumps was 87% (95% confidence interval, 86%-87%). Our data indicates that, in Korean HCWs, testing for mumps antibody followed by mumps vaccination is more appropriate than routine mumps vaccination without testing for mumps antibody.

Keyword

Mumps; Measles-mumps-rubella vaccine; Health personnel; Seroepidemiologic studies

MeSH Terms

Delivery of Health Care*
Health Personnel
Humans
Korea*
Measles-Mumps-Rubella Vaccine
Mumps*
Republic of Korea
Seroepidemiologic Studies*
Tertiary Healthcare
Vaccination
Measles-Mumps-Rubella Vaccine

Figure

• 

  Fig. 1 Seroprevalence of mumps immunoglobulin G antibodies in healthcare workers in 2018. The circles denote the mean seropositivity rate (%) and error bars denote 95% confidence intervals, and the dashed line denotes 75% and 86% seropositivity rates.

Reference

1. Rubin SA. Mumps vaccines: modes of transmission. In : Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin's vaccines. 7th ed. Philadelphia, PA: Elsevier;2018. p. 663–688.

2. Fine PM. Community protection: case reproduction numbers. In : Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin's vaccines. 7th ed. Philadelphia, PA: Elsevier;2018. p. 1512–1531.

3. Park SH. Resurgence of mumps in Korea. Infect Chemother. 2015; 47:1–11.

4. Korea Centers for Infectious Disease Control. Measles and rubella elimination and current status in Korea [Internet]. Cheongju: Korea Centers for Disease Control and Prevention;2018. cited 2018 Nov 1. Available from: https://www.cdc.go.kr/board.es?mid=a20602010000&bid=0034&list_no=141655&act=view#.

5. Korea Centers for Infectious Disease Control. Infectious disease surveillance yearbook (2018). Cheongju: Korea Centers for Disease Control and Prevention;2019.

6. Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60:1–45.

7. Anderson RM, Crombie JA, Grenfell BT. The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization. Epidemiol Infect. 1987; 99:65–84.

8. Anderson RM, May RM. Immunisation and herd immunity. Lancet. 1990; 335:641–645.

9. Plans P. New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population. Eur J Clin Microbiol Infect Dis. 2013; 32:961–966.

10. Kim KH, Ki H, Choi BY, et al. Evaluation of mumps vaccine effectiveness by outbreak investigation in one kindergarten in Ulsan city, 2006. Korean J Epidemiol. 2008; 30:110–118.

11. Jung J, Kim SK, Kwak SH, Hong MJ, Kim SH. Seroprevalence of measles in healthcare workers in South Korea. Infect Chemother. 2019; 51:58–61.

12. Seagle EE, Bednarczyk RA, Hill T, et al. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. Vaccine. 2018; 36:818–826.

13. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008; 197:950–956.

14. Choe YJ, Eom HE, Cho SI. Trend of measles, mumps, and rubella incidence following the measles-rubella catch up vaccination in the Republic of Korea, 2001. J Med Virol. 2017; 89:1528–1531.